Table 1.
Summary of studies included in the quantitative analysis
| N | % | |||
|---|---|---|---|---|
| Total number of studies included | 96 | |||
| Original articles | 82 | 85.4 | ||
| Abstracts | 14 | 14.6 | ||
| Year of publication | ||||
| 2009 | 6 | 6.3 | ||
| 2010 | 7 | 7.3 | ||
| 2011 | 8 | 8.3 | ||
| 2012 | 12 | 12.5 | ||
| 2013 | 17 | 17.7 | ||
| 2014 | 29 | 30.2 | ||
| 2015 | 17 | 17.7 | ||
| Global distribution of location of institutions of selected studies | ||||
| North America | 54 | 56.3 | ||
| Europe | 21 | 21.9 | ||
| Asia | 18 | 18.7 | ||
| Australia/Africa/South America (1 each) | 3 | 3.1 | ||
| Single vs multi-institutional | ||||
| Single institution | 83 | 86.5 | ||
| Multi-institutional | 13 | 13.5 | ||
| Type of study | ||||
| Retrospective series | 54 | 56.3 | ||
| Phase 2 studies | 22 | 22.9 | ||
| Prospective series | 11 | 11.5 | ||
| Phase 1 studies | 5 | 5.2 | ||
| Phase 1/2 studies | 3 | 3.1 | ||
| Phase 3 studies | 1 | 1 | ||
| Criteria for resectability | ||||
| NCCN/AHPBA/SSO/SSAT consensus | 38 | 39.6 | ||
| MD Anderson | 8 | 8.3 | ||
| Other | 29 | 30.2 | ||
| Not mentioned | 21 | 21.9 | ||
| Number of studies of each local/anatomical stage | ||||
| Resectable | 18 | 18.8 | ||
| Borderline resectable (BR) | 15 | 15.6 | ||
| Locally advanced unresectable (LA) | 29 | 30.2 | ||
| R + BR | 5 | 5.2 | ||
| BR + LA | 24 | 25 | ||
| R + BR + LA | 5 | 5.2 | ||
| Number of patients in each anatomical stage | ||||
| Resectable | 1056 | 19.1 | ||
| Borderline resectable (BR) | 935 | 16.9 | ||
| Locally advanced unresectable (LA) | 1840 | 33.3 | ||
| R + BR | 202 | 3.7 | ||
| BR + LA | 1014 | 18.4 | ||
| R + BR + LA | 473 | 8.6 | ||
| Criteria for of radiology response assessment | ||||
| RECIST | 48 | 50 | ||
| WHO | 5 | 5.2 | ||
| Other | 2 | 2.1 | ||
| Not mentioned | 41 | 42.7 | ||
| Criteria for toxicity assessment | ||||
| NCI CTCAE | 43 | 44.8 | ||
| WHO | 5 | 5.2 | ||
| RTOG | 2 | 2.1 | ||
| Not mentioned/not applicable | 46 | 47.9 | ||
| Type of neoadjuvant therapy | ||||
| Chemoradiotherapy | 33 | 34.4 | ||
| Chemotherapy alone | 20 | 20.8 | ||
| Chemotherapy with chemoradiation | 41 | 42.7 | ||
| Radiation alone | 2 | 2.1 | ||
| Chemotherapy drugs | ||||
| Monotherapy (Gem/5FU/Cape/UFT/Cis) | 26 | 27.1 | ||
| FOLFIRINOX | 20 | 20.8 | ||
| Gemcitabine + oxaliplatin* | 8 | 8.3 | ||
| Gemcitabine or 5FU + cisplatin | 7 | 7.3 | ||
| Gemcitabine + Docetaxel | 3 | 3.1 | ||
| GTX (gemcitabine, taxane, capecitabine) | 6 | 6.3 | ||
| Gem + biologic (bevacizumab, cetuximab) | 3 | 3.1 | ||
| Gem + S1 | 5 | 5.2 | ||
| Gem + Nab-paclitaxel | 2 | 2.1 | ||
| 5FU + cisplatin + interferon | 1 | 1 | ||
| Multiple | 11 | 11.5 | ||
| Not mentioned | 2 | 2.1 | ||
| None | 2 | 2.1 | ||
| Radiotherapy | ||||
| Yes | 76 | 79.2 | ||
| No | 20 | 20.8 | ||
*Includes one study with gemcitabine + oxaliplatin + cetuximab
R resectable, BR borderline resectable, LA locally advanced, Gem Gemcitabine, Cape capecitabine, 5FU 5 Fluorouracil, UFT uracil/tegafur